Synergistic effect of Ru(II)-based type II photodynamic therapy with cefotaxime on clinical isolates of ESBL-producing Klebsiella pneumoniae
Date Issued
2023-08
Author(s) USM
Dreyse, Paulina
DOI
10.1016/j.biopha.2023.114949
Abstract
Multidrug-resistant bacteria, such as ESBL producing-Klebsiella pneumoniae, have increased substantially, encouraging the development of complementary therapies such as photodynamic inactivation (PDI). PDI uses photosensitizer (PS) compounds that kill bac
Política de Privacidad 
